TECNOTREE
10.12.2020 13:55:11 CET | Business Wire | Press release
Further to the notification published on 30th June 2020, Tecnotree, the global provider of digital solutions for the telecom industry, has announced a strategic partnership with Kuwait Telecommunications Company - stc , a world-class digital leader providing innovative services and platforms to customers enabling the digital transformation in Kuwait, to deliver stc’s Enterprise Digitalization Program (EDP). The digital transformation project will provide stc ’s enterprise customers with a seamless and personalized omnichannel experience.
In its statement, stc mentioned that the three-year partnership supports the company’s vision to become a world-class digital leader in innovative telecom services and platforms across the region. The step forward will contribute to enhancing the customer experience through innovative solutions, facilitating business processes efficiently and expediting customer service responses across the various channels used by the company.
The EDP aims to transform stc ’s legacy BSS infrastructure with an open ecosystem composed of multi-speed digital architecture, enabling the company to rapidly deploy new capability models and integrate both partner and third-party digital channels into a single framework.
Tecnotree’s vast experience in driving digital transformation engagements globally will underpin the program. As stc ’s partner on this journey, Tecnotree brings unique capabilities to the project via its Digital BSS Suite 5 products, including Tecnotree Surge, an award-winning Digital Accelerator Platform that publishes TM Forum certified APIs. The two companies will use these tools together to help stc transition to a digital service provider of the future, enabling it to compete in the new digital telecom paradigm.
Engineer Fahad Abdulrahman Al Ali, Chief Technology Officer at stc, expressed his happiness in forming the strategic partnership, which serves as an additional step taken by the company to widen its offerings, its range of innovative digital solutions, and build the infrastructure of its 5G network.
He added, “Upgrading our digital services will provide our customers with enhanced connectivity solutions, thereby accelerating the deployment of smart applications and promoting digital transformation. This initiative builds on stc ’s commitment to continuously offer its enterprise customers with less restricted solutions that accelerate digital transformation with an aim to increase productivity and operational efficiency.”
Upon completion, the multi-phased transformation project will upgrade stc ’s current systems to state-of-the-art IT architecture and processes that will allow delivery of seamless and personalized omnichannel customer experiences via leveraging intelligent insights. This will enable stc to become a full digital ICT player and system integrator, whilst also expanding its services & solutions beyond mobility.
Commenting on the strategic partnership, Tecnotree CEO, Padma Ravichander, said, “We are delighted that stc has selected our award-winning Digital BSS Suite to support their digital transformation journey. As a world class digital leader, they have recognised that digitalization has become a core necessity to compete in today’s telecom industry. We look forward to using our TM Forum Gold-Badge certified products and years of global digital transformation experience to help stc emerge as the leader in the digitally connected ecosystem.”
View source version on businesswire.com: https://www.businesswire.com/news/home/20201210005533/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Consortium Led by Axelspace Selected for Japan’s Space Strategy Fund Project “Technology to Enhance Capability of Next Generation Earth Observation Satellites”30.3.2026 01:35:00 CEST | Press release
~ Creating Climate Solutions and New Market Opportunities through Source-Specific CO2 Emission and Uptake Monitoring via Satellite Constellation and Aircraft ~ Axelspace Corporation, Meisei Electric Co., Ltd., ANA HOLDINGS INC., and JIJ Inc. are pleased to announce that their jointly proposed technology development project has been selected for Japan Aerospace Exploration Agency (JAXA)’s Space Strategy Fund under the theme “Technology to Enhance Capability of Next Generation Earth Observation Satellites.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260323044518/en/ Conceptual Diagram of the project. Under this Space Strategy Fund initiative, spectrometers will be newly developed and demonstrated in orbit. In the future, the project envisions the establishment of a satellite constellation capable of observations at different times of the day. Project Summary (Planned) Technology Development Theme: Technology to Enhance Cap
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom